Compensated Awareness Post View
Disclaimer
MITD Benefits from Requirements of Documentation and Value-Based Healthcare Options
The healthcare industry is in the midst of a substantial shift away from traditional fee-for-service payments, which have historically been associated with excessive and unnecessary care, in favor of value-based options. In January, the Centers for Medicare and Medicaid Services reaffirmed this fact when it announced a goal of having 50 percent of all Medicare payments in alternative payment models by the end of 2018. MIT Holding, Inc. (OTCQB: MITD), a leading provider of post-acute care nationwide, is in a strong position to capitalize on this evolving mindset by providing ambulatory care, in-home intravenous therapies, medical equipment and other recovery needs to help patients avoid unnecessary doctor and hospital visits.
According to a report by Fox Business, the total reduction in overall healthcare spending as a result of ambulatory surgery and therapy options amounts to approximately $2.6 billion annually, and an additional $2.4 billion in savings could be realized if just 50 percent of eligible cases were moved to these non-hospital settings. For MITD, these potential savings could translate into improved financial returns in the coming months. Demand for the company’s low cost, high quality home care is expected to rise as payers realize up to 90 percent savings on infusion services performed in the home instead of the hospital.
The potential market for MITD’s home infusion services is vast. According to Harris Williams & Co., the United States home infusion market is currently valued at $15.9 billion, and continued growth is expected to push the market to $26.7 billion by 2020. In the first quarter of 2015, the company made significant strides toward maximizing its share of this pivotal sector by recording just under $490,000 in consolidated revenues, which was a year-over-year increase of over 133 percent. Leveraging an increase in referrals and the strategic use of subcontractors, MITD also realized a gross profit of nearly $278,000 for the period.
“Our target audience is focused on those needing infusion for recovery,” Tommy Duncan, president of MITD, stated in a news release. “Our platform is based on the delivery of these high cost, specialty pharmaceuticals that have specialized handling and administration requirements.”
For prospective investors, MITD’s strong financial results in recent quarters, as well as the increasing demand for its value-based services, could provide the company with a platform to deliver strong returns moving forward. Look for MITD to continue building on its established position within the ambulatory care market in order to capitalize on rising demand in the years to come.
For more information on MIT Holding, visit www.mitholdinginc.com
